{
    "N/R/U": null,
    "Applicant": "Ferring Pharmaceuticals A/S",
    "BLA Number": "125700",
    "Proprietary Name": "Adstiladrin",
    "Proper Name": "nadofaragene firadenovec-vncg",
    "BLA Type": "351(a)",
    "Strength": "3x10^11 viral particles (vp)/mL",
    "Dosage Form": "For Suspension",
    "Route of Administration": "Intravesical",
    "Product Presentation": "Single-Dose Vial",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "December 16, 2022",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": "0",
    "Submission Type": "Original",
    "License Number": "2222",
    "Product Number": "001",
    "Center": "CBER",
    "Date of First Licensure": "December 16, 2022",
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": "December 16, 2034",
    "Orphan Exclusivity Exp. Date": null
}